The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese patients without Diabetes: A Systematic Review and Meta-Analysis
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1844-1176
Horm Metab Res DOI: 10.1055/a-1844-1176 Original Article: Endocrine Care 9 , Dongcheng-qu, China (Ringgold ID: RIN34732) › Author AffiliationsSupported by: CAMS Innovation Fund for Medical Sciences (2021-1-I2M-002Supported by: National...
Conclusion: Our meta-analysis demonstrated that GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC, especially for semaglutide, which had more obvious antiobesity effect and lower GI adverse events than liraglutide and exenatide.
Sciatic nerve microvascular permeability in type 2 diabetes decreased in patients with neuropathy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35488789/
This study is the first to find associations of MR nerve perfusion parameters with clinical and electrophysiological parameters related to DN in T2D. The results indicate that a decrease in...
Conclusion: This study is the first to find associations of MR nerve perfusion parameters with clinical and electrophysiological parameters related to DN in T2D. The results indicate that a decrease in microvascular permeability but not plasma volume may result in nerve ischemia that subsequently causes demyelination.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35468322/
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients with long-standing type 2 diabetes to achieve normoglycaemia. We...
Interpretation: The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely β-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable glucose-lowering ability of...
Add-on value of tirzepatide versus semaglutide
Source : https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00116-4/fulltext
Type 2 diabetes is a complex disease with several key defects, including impaired insulin secretion, increased glucagon secretion, and insulin resistance, which is exacerbated by obesity. Thus, besides lifestyle measures,...
Conclusion: Overall, GLP-1 receptor agonists are regarded as crucial in the most recent international guidelines for the management of type 2 diabetes, especially in patients with atherosclerotic cardiovascular disease or obesity.
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35484580/
doi: 10.1186/s12933-022-01489-6. 1 Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Peter Munk Cardiac Centre, Toronto General Hospital, 200 Elizabeth St, PMCRT 3-904, M5G2C4, Toronto, Canada....
Conclusions: Our study implies that Liraglutide protects the cardiac, cerebral and renal microvasculature against diabetes-induced dysfunction, independent of lowering blood glucose in a type 1 diabetes rat model.